MWM
XENE icon

Moran Wealth Management’s Xenon Pharmaceuticals XENE Stock Holding History

Moran Wealth Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-69,510
Closed -$2.37M – 461
2023
Q3 		$2.37M Buy
69,510
+580
+0.8% +$21.7K 0.09% 206
2023
Q2 		$2.65M Buy
68,930
+1,317
+2% +$52.4K 0.1% 200
2023
Q1 		$2.42M Buy
+67,613
New +$2.5M 0.09% 209

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Moran Wealth Management's XENE Position: Q4 2023 in Review

Moran Wealth Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2023, closing a stake of 69,510 shares — an estimated $2.37M sold.

Moran Wealth Management first reported a position in XENE in Q1 2023 and held it in 3 quarters. The position peaked at $2.65M in Q2 2023. 204 funds tracked by Wall St. Rank hold XENE as of Q4 2023.

  • Moran Wealth Management reported no remaining Xenon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Moran Wealth Management sold 69,510 Xenon Pharmaceuticals shares in Q4 2023, an estimated $2.37M.
  • Moran Wealth Management first reported a position in Xenon Pharmaceuticals in Q1 2023 and held it in 3 quarters.
  • Moran Wealth Management's Xenon Pharmaceuticals position peaked at $2.65M in Q2 2023.
  • 204 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2023.

Based on Moran Wealth Management's 13F filing for Q4 2023, filed 8 Feb 2024.